See more : Q Technology Group Limited (QTG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BerGenBio ASA (BGBIO.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BerGenBio ASA, a leading company in the Biotechnology industry within the Healthcare sector.
- PetroChina Company Limited (PECN.VI) Income Statement Analysis – Financial Results
- HeiQ Plc (HEIQ.L) Income Statement Analysis – Financial Results
- Strategic Energy Resources Limited (SER.AX) Income Statement Analysis – Financial Results
- Lin BioScience, Inc. (6696.TWO) Income Statement Analysis – Financial Results
- Ringmetall SE (HP3A.DE) Income Statement Analysis – Financial Results
BerGenBio ASA (BGBIO.OL)
About BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 354.00K | 389.00K | 774.00K | 601.00K | 8.90M | 2.34M | 0.00 | 0.00 | 0.00 | 598.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 89.47M | 65.25M | 66.49M | 193.00K | 207.00K | 179.00K | 0.00 |
| Gross Profit | 354.00K | 389.00K | 774.00K | -88.87M | -56.35M | -64.16M | -193.00K | -207.00K | -179.00K | 598.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | -14,786.69% | -633.15% | -2,747.67% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 107.79M | 8.34M | 12.74M | 21.79M | 21.23M | 10.29M | 12.52M | 17.04M | 4.63M | 5.69M |
| General & Administrative | 0.00 | 0.00 | 12.74M | 21.79M | 21.23M | 10.29M | 12.52M | 17.04M | 4.63M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 84.39M | 105.06M | 12.74M | 21.79M | 21.23M | 10.29M | 12.52M | 17.04M | 4.63M | 0.00 |
| Other Expenses | 0.00 | 297.68M | 289.75M | 218.11M | 170.83M | 186.58M | 171.19M | 782.00 | 299.00 | 1.00K |
| Operating Expenses | 192.17M | 306.02M | 315.24M | 261.69M | 213.28M | 196.87M | 183.71M | 131.57M | 72.93M | 59.42M |
| Cost & Expenses | 192.17M | 306.02M | 315.24M | 261.69M | 213.28M | 196.87M | 183.71M | 131.57M | 72.93M | 59.42M |
| Interest Income | 3.06M | 2.95M | 3.13M | 4.42M | 2.26M | 3.52M | 2.81M | 1.54M | 1.49M | 2.30M |
| Interest Expense | 578.00K | 321.00K | 53.00K | 32.00K | 109.00K | 47.00K | 31.00K | 25.00K | 258.00K | 1.26M |
| Depreciation & Amortization | 223.00K | 883.00K | 1.31M | 726.00K | 785.00K | 204.00K | 193.00K | 207.00K | 179.00K | 179.00K |
| EBITDA | -189.60M | -300.92M | -308.00M | -260.92M | -198.38M | -191.54M | -183.51M | -131.36M | -72.75M | -57.51M |
| EBITDA Ratio | -53,559.32% | -77,356.81% | -39,793.15% | -42,640.77% | -2,229.03% | -8,201.11% | 0.00% | 0.00% | 0.00% | -9,421.40% |
| Operating Income | -191.82M | -305.64M | -314.46M | -261.09M | -204.37M | -194.54M | -183.71M | -131.57M | -72.93M | -58.82M |
| Operating Income Ratio | -54,186.16% | -78,569.41% | -40,628.42% | -43,442.76% | -2,296.34% | -8,331.43% | 0.00% | 0.00% | 0.00% | -9,836.79% |
| Total Other Income/Expenses | 1.42M | 3.51M | 5.10M | 4.06M | 5.10M | 2.79M | 1.50M | 1.77M | 818.00K | 1.04M |
| Income Before Tax | -190.40M | -302.12M | -309.36M | -257.03M | -199.28M | -191.75M | -182.21M | -129.80M | -72.11M | -57.78M |
| Income Before Tax Ratio | -53,785.59% | -77,666.32% | -39,969.51% | -42,766.89% | -2,239.08% | -8,211.86% | 0.00% | 0.00% | 0.00% | -9,662.21% |
| Income Tax Expense | 0.00 | -3.51M | 53.00K | 32.00K | 109.00K | 2.84M | 1.53M | 1.80M | 1.08M | 2.31M |
| Net Income | -190.40M | -298.61M | -309.42M | -257.06M | -199.39M | -191.75M | -182.21M | -129.80M | -72.11M | -57.78M |
| Net Income Ratio | -53,785.59% | -76,763.24% | -39,976.36% | -42,772.21% | -2,240.30% | -8,211.86% | 0.00% | 0.00% | 0.00% | -9,662.21% |
| EPS | -13.30 | -38.65 | -40.36 | -39.37 | -38.76 | -40.60 | -45.19 | -29.44 | -16.35 | -13.11 |
| EPS Diluted | -13.30 | -38.65 | -40.36 | -39.37 | -38.76 | -40.60 | -45.19 | -29.44 | -16.35 | -13.11 |
| Weighted Avg Shares Out | 14.31M | 7.73M | 7.67M | 6.53M | 5.14M | 4.72M | 4.03M | 4.41M | 4.41M | 4.41M |
| Weighted Avg Shares Out (Dil) | 14.31M | 7.73M | 7.67M | 6.53M | 5.14M | 4.72M | 4.03M | 4.41M | 4.41M | 4.41M |
Source: https://incomestatements.info
Category: Stock Reports